ANI Strikes Deal With Coeptis For Seven Development-Stage Assets
Continuing its acquisition streak, ANI Pharmaceuticals has bought a pipeline of seven development-stage generics from Coeptis Pharmaceuticals for $2.3m in cash and up to $12m in development and commercial milestone payments.
You may also be interested in...
Having swelled its pipeline of US injectable drugs through an acquisition, ANI Pharmaceuticals is on the lookout for attractive manufacturing assets.
US niche generics and brands player ANI Pharmaceuticals intends to keep using its cash flow to fund product acquisitions and partnerships, particularly in the injectables arena.
The US Supreme Court has lifted a stay on document discovery in a multi-state lawsuit in which dozens of generics companies – including Teva, Mylan and Pfizer – are accused of price fixing. The ruling will allow a swathe of documents to be released in what Connecticut’s attorney general has said is potentially “the largest cartel case” in US history.